Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia.

"Financial/nonfinancial disclosures: The authors have reported to CHEST the following: M. d. W. reports grant support from the PETAL network. M. N. G. reports personal consulting fees for serving on the scientific advisory panel for Endpoint Health and Philips Healthcare, support for attending ATS board meetings, and participation on a data safety monitoring board for Regeneron. A. A. G. reports grant support from Faron Pharmaceuticals and AbbVie and participation on data safety monitoring boards for studies at 10.13039/100013017Vanderbilt University Medical Center and the University of Wisconsin. S. M. B. serves as the chair of the data safety monitoring board for Hamilton Ventilators. C. J. L. reports grant support from bioMerieux, Entegrion, Inc., Endpoint Health, and AbbVie; patents issued to Cincinnati Children’s Hospital Medical Center for risk stratification in sepsis and septic shock; participation on data safety monitoring boards for clinical trials unrelated to the current work, stock options in Bioscape Digital (unrelated to the current work), and leadership roles (executive committee, immediate past president, member, board of directors) for the Association for Clinical and Translational Science. S. P. C. reports personal consulting fees from Vir Biotechnology. None declared (A. M., M. S. S., K. W. G., M. H., Y. R., J. T., L. H. M., D. C. F., K. H., B. T. T., D. J. D., E. R., M. M. J., L. W., G. R. B., M. W. S., W. H. S.)."

"Funding /support: This research was funded in part by the National Heart, Lung and Blood Institute, National Institutes of Health [Grants 42-312-0217571-66406L and 10T2HL156812]."